- SELLAS Life Sciences (SLS) has surged 550% in the past year, driven by technical momentum and speculative trading.
- SLS currently has no revenue, with all products in development or clinical trials, making the stock highly speculative.
- Technical indicators are overwhelmingly bullish, but high short interest highlights significant risk.
- Sentiment is mixed: Barchart and Value Line are bullish, while Morningstar and Seeking Alpha rate SLS as “Hold” or suggest it is overvalued.